title: [Prevalence of extended-spectrum beta-lactamase producing Escherichia coli in pediatric patients in China].
abstract: OBJECTIVE
  To study the drug resistance profiles of extended spectrum beta lactamase (ESBL) producing Escherichia coli (E. coli) and provide guidance for pediatric clinical prescription.
  
  
  METHODS
  5127 strains of ESBL producing E. coli were isolated from 5 children's hospitals in Beijing, Shanghai, Chongqing, and Guangzhou. The minimum inhibitory concentration (MIC) values of 349 strains to 9 antibiotics most in use in pediatrics were measured with agar dilution method.
  
  
  RESULTS
  The prevalent rate of ESBL producing of E. coli was 46.7%. The resistant rates to ampicillin/clavulanic acid, cefotaxime, ceftazidime, and cefepime were 23.1%, 67.2%, 24.5%, and 48.4% respectively, and the intermediate rates were 38.5%, 26.4%, 5.7%, and 19.1% respectively. The resistant rate to amikacin was 5.4%. All the strains were susceptible to imipenem. The MIC90 values of ampicillin, cefotaxime, cefepime, ciprofloxacin, and gentamicin were 256 mg/L or higher. There were differences in the resistance profile to ampicillin/clavulanic acid, cefepime, ciprofloxacin, and gentamicin among different regions.
  
  
  CONCLUSIONS
  ESBL is extensively prevalent among the E. coli strains isolated from the pediatric clinic that are resistant to most antimicrobial agents except imipenem and amikacin. Regional difference exists in drug resistance to some agents exist.
authors.affiliation: Microbiology and Immunology Department, Pediatric Research Institute, Beijing Children's Hospital Affiliated to Capital Medical University, Beijing 100045, China.
authors.forename: Li
authors.initials: L
authors.lastname: Wang
authors.forename: Yong-hong
authors.initials: YH
authors.lastname: Yang
authors.forename: Quan
authors.initials: Q
authors.lastname: Lu
authors.forename: Yi
authors.initials: Y
authors.lastname: Wang
authors.forename: Yuan
authors.initials: Y
authors.lastname: Chen
authors.forename: Li
authors.initials: L
authors.lastname: Deng
authors.forename: Qiu-lian
authors.initials: QL
authors.lastname: Deng
authors.forename: Hong
authors.initials: H
authors.lastname: Zhang
authors.forename: Chuan-qing
authors.initials: CQ
authors.lastname: Wang
authors.forename: Lan
authors.initials: L
authors.lastname: Liu
authors.forename: Xi-wei
authors.initials: XW
authors.lastname: Xu
authors.forename: Xu-zhuang
authors.initials: XZ
authors.lastname: Shen
mesh_terms: D000890:Anti-Infective Agents / Q000494:pharmacology; D002648:Child; D002675:Child, Preschool; D002681:China / Q000453:epidemiology; D024901:Drug Resistance, Multiple, Bacterial; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology* / Q000378:metabolism; D004927:Escherichia coli Infections / Q000453:epidemiology / Q000382:microbiology*; D029968:Escherichia coli Proteins / Q000378:metabolism*; D006776:Hospitals, Pediatric / Q000706:statistics & numerical data; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008826:Microbial Sensitivity Tests; D015995:Prevalence; D018440:beta-Lactam Resistance; D001618:beta-Lactamases / Q000378:metabolism*; D047090:beta-Lactams / Q000494:pharmacology
chemical_list: D000890:Anti-Infective Agents; D029968:Escherichia coli Proteins; D047090:beta-Lactams; D001618:beta-Lactamases